Event-Driven Stocks

InMed Pharmaceuticals Inc.

INMNasdaq

Healthcare · Pharmaceutical Preparations · A1 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 2 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$4.9M$4.6M$1.4M$1.4M$1.9M—
Operating income——−$7.9M−$18.6M−$10.2M—
Net income−$8.2M−$7.7M−$7.9M−$18.6M−$10.2M−$8.9M
Total assets$15.6M$11.8M$14.1M$12.8M$9.8M$7.8M
Total liabilities$2.1M$2.6M$2.0M$3.7M$2.4M$1.9M
Equity$13.4M$9.2M$12.1M$9.1M$7.4M$5.9M
EPS (diluted)$-8.36$-20.14$-3.25$-33.17$-37.96—
Shares out.2.4M13.3M3.3M908,7619.4M5.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
−165.1%
Return on equity
−60.8%
Return on assets
−52.4%
Return on capital (ROCE)
—
Liabilities / assets
13.8%
Debt / equity
0.16×
Book value / share
$5.63
Revenue growth (YoY)
7.5%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−2.5%clean
Beneish M-Score
-2.51normal
Piotroski F-Score
5/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
60
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 1 severe● 2 warning● 3 good
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202626,5991.4-25.0%
Apr 30, 202635,4691.2-62.9%
Apr 15, 202695,6362.7+3.9%
Mar 31, 202692,0631.0+38.2%
Mar 13, 202666,6141.0-27.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.